Furthermore, we identified XPO1 as a potential diagnostic and therapeutic target for ccRCC, as it was found to be involved in the activation of PI3K-AKT-mTOR and interferon-alpha pathways, thereby promoting renal cancer progression. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.